AlphaYou
Overview
8 funds hold it, insiders have been net selling, and 1 straight earnings miss.
Key stats
Sep 7- Open
- $162.82
- 52-wk high
- $209.11
- High
- $163.78
- 52-wk low
- $143.33
- Low
- $161.13
- Prev close
- $164.77
- Mkt cap
- $252.33B
- P/E
- 24.3x
- Volume
- 3.07M
- Fwd P/E
- 14.4x
- Beta
- 0.20
- Div yield
- 1.96%
- P/S
- 4.1x
- P/B
- 5.1x
- Profit margin
- +17.0%
- Op margin
- +23.5%
- ROE
- +22.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 12.8% below what analysts expected.
Earnings per share
$2.50 expected
What the street expects next
EPS expected
$1.25 to $1.31
Revenue expected
9 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.19B | $15.50B | $15.29B | $15.38B |
| Cost of what it sold | $2.80B | $3.12B | $2.68B | $2.52B |
| Gross profit | $12.39B | $12.38B | $12.61B | $12.86B |
| What it spent | ||||
| Research and development | $3.66B | $3.86B | $3.49B | $4.05B |
| Sales and admin | $5.08B | $5.49B | $4.92B | $5.65B |
| Total operating expenses | $8.81B | $9.41B | $8.36B | $9.70B |
| What was left | ||||
| Operating profit | $3.58B | $2.98B | $4.25B | $3.16B |
| Interest on debt | $434.0M | $472.0M | $393.0M | $435.0M |
| Profit before tax | $3.24B | $2.63B | $3.91B | $2.80B |
| Tax | $709.0M | $300.0M | $833.0M | $291.0M |
| Net profit | $2.53B | $2.33B | $3.08B | $2.51B |
| EBITDA | $5.23B | $4.61B | $5.67B | $5.16B |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
AstraZeneca’s GRACE Study: Real-World Data On Greek Gastric Cancer Care
Leans bullishSep 3AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer
BullishSep 1AstraZeneca Loses Suit Seeking Block on Colorado Pharmacy Law
BearishSep 1AstraZeneca slides Friday, underperforms market
BearishAug 28AstraZeneca slides Wednesday, underperforms market
NeutralAug 26AstraZeneca climbs Tuesday, outperforms market
BullishAug 25AstraZeneca (AZN) lines up €2.55B in new Eurobonds
NeutralAug 25AstraZeneca PLC : Gets a Sell rating from Deutsche Bank
BearishAug 25
Macro
20 macro signals shaping AZN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results